Trius said revenue was higher in 2011 because it received a $25 million one-time payment from its partner Bayer Pharma AG. Bayer is helping Trius develop its flagship antibiotic, tedizolid phosphate.The antibiotic treats "superbug infections, such as MRSA, or methicillin-resistant Staphylococcus aureus.Trius increased research and development expenses to $69 million in 2012 from $49.5 million in